文献速递肺外科

多孔胸腔镜肺叶特异性纵隔淋巴结清扫后的肿瘤学结局

Oncological outcomes after lobe-specific mediastinal lymph node dissection via multiport video-assisted thoracoscopic surgery.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该回顾性研究纳入660例接受多孔胸腔镜肺叶切除联合肺叶特异性纵隔淋巴结清扫的临床T1-3N0M0非小细胞肺癌患者,其中54例(8.2%)病理淋巴结阳性(18例N1,36例N2)。中位随访51.6个月,pN1和pN2患者5年总生存率分别为88.1%和80.0%,无复发生存率分别为63.9%和34.8%;省略区复发是该清扫方式的关注点。

要点

  • pN1患者 adequate MLND 是治愈关键,pN2患者复发后全身治疗可能贡献生存。
  • pN2患者中,病理T分期是OS(P<0.001)和RFS(P=0.034)的预后因素。
  • 单站N2疾病也是OS的预后因素(P=0.023)。

核心结论

  • 省略区复发是肺叶特异性MLND的问题;pN1患者充分MLND是治愈重要因素,pN2患者复发后全身治疗也可能贡献生存。

研究设计与样本

  • 回顾性研究,2008年4月至2016年12月共660例临床T1-3N0M0非小细胞肺癌患者接受VATS肺叶切除联合肺叶特异性MLND,其中54例(8.2%)病理淋巴结阳性(18例N1,36例N2)。

主要发现

  • 主要组织学类型为腺癌(87%)。
  • pN1中6例(33%)、pN2中11例(31%)接受辅助化疗。
  • 中位随访51.6个月,pN1中5例(28%)、pN2中22例(61%)出现术后复发。
  • pN1中1例(6%)、pN2中12例(33%)发生局部区域复发;pN1无患者在清扫区局部复发,pN2中11例(31%)淋巴结复发,包括4例在清扫区、3例在肺叶特异性MLND省略区。
  • pN1和pN2的5年总生存率分别为88.1%和80.0%,5年无复发生存率分别为63.9%和34.8%。

关键数值与推荐

  • pN2患者中,病理T分期是总生存(P < 0.001)和无复发生存(P = 0.034)的预后因素。
  • pN2患者中,单站N2疾病也是总生存的预后因素(P = 0.023)。

临床怎么用

  • 对pN1患者应确保充分的肺叶特异性MLND以追求治愈。
  • 对pN2患者需关注省略区复发风险,复发后全身治疗可能改善生存。

局限性

  • 回顾性研究设计。
  • 病理淋巴结阳性样本量较小(54例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We retrospectively investigated oncological outcomes after video-assisted thoracoscopic surgery (VATS) lobectomy with lobe-specific mediastinal lymph node dissection (MLND). METHODS: Between April 2008 and December 2016, a total of 660 patients underwent VATS lobectomy with lobe-specific MLND for clinical T1-3N0M0 non-small-cell lung cancer, of which 54 (8.2%) patients had pathological node-positive disease (18 N1 and 36 N2). We evaluated their oncological outcomes. RESULTS: The predominant histological type was adenocarcinoma (87%). Six (33%) patients in the pN1 and 11 (31%) patients in the pN2 received adjuvant chemotherapy. The median follow-up period was 51.6 months. Postoperative recurrence was observed in 5 (28%) pN1 and 22 (61%) pN2 patients. One (6%) pN1 and 12 (33%) pN2 patients experienced locoregional recurrence. None of the pN1 patient experienced local recurrence at the dissected zone, whereas 11 (31%) pN2 patients had lymph node recurrence, including four at the dissected area and three in the area omitted from dissection in the lobe-specific MLND. The 5-year overall survival rates were 88.1% in the pN1 patients and 80.0% in the pN2 patients; the 5-year recurrence-free survival rates were 63.9% in the pN1 patients and 34.8% in the pN2 patients. In pN2 patients, pathological T classification was a prognostic factor for overall survival (P < 0.001) and recurrence-free survival (P = 0.034), and single-station N2 disease was also prognostic factor for overall survival (P = 0.023). CONCLUSIONS: Recurrence at the omitted zone is an issue for this type of MLND. For pN1 patients, adequate MLND is an important factor for curative treatment. However, for pN2 patients, systemic treatment after recurrence may also contribute to survival.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Mun M, Nakao M, Matsuura Y, et al. Oncological outcomes after lobe-specific mediastinal lymph node dissection via multiport video-assisted thoracoscopic surgery. Eur J Cardiothorac Surg. 2020. PMID: 32533183. doi:10.1093/ejcts/ezaa166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。